Q-omics provides the consensus-scored LMAN1 profile across patient tissues and cancer cell-line models. LMAN1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LMAN1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LMAN1 protein abundance shows 24,710 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, KIRC, and GBM as cancer lineages where LMAN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMAN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMAN1 survival associations across molecular data types. LMAN1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMAN1 RNA expression–survival associations across cancer types. High LMAN1 expression shows unfavorable associations in BLCA, ACC, UVM, LGG, MESO and KIRP. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LMAN1 RNA expression.
This table summarizes LMAN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LMAN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMAN1 shows lower tumor expression in THCA and higher tumor expression in KIRC, BLCA, HNSC, BRCA and LUAD. The KIRC box plot shows higher LMAN1 RNA expression in tumor versus normal tissue (log2 FC = +0.601, t-test p < 0.001).
This table shows molecular features associated with LMAN1 in patient tissues and cancer cell lines. In patient samples, LMAN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LMAN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
